Month: April 2020

The share capital decrease by reduction in par value per share from NOK 2.20 to 0.11, as resolved by the Extraordinary General Meeting in Thin Film Electronics ASA on 15 April 2020, has today been registered in the Register of Business Enterprises. Following such registration, the Company’s share capital is 6,445,293.91 divided into 58,593,581 shares, each share having a par value of NOK 0.11.###Thinfilm is Energizing InnovationTM with ultrathin, flexible, and safe energy storage solutions for wearable devices, connected sensors, and beyond. Thinfilm’s innovative solid-state lithium battery (SSLB) technology is uniquely positioned to enable the production of powerful, lightweight, and cost-effective rechargeable batteries for diverse applications. The company’s state-of-the-art flexible electronics manufacturing facility, located in the...

Prospective, randomized, single‑blinded, multi‑center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceConclusion: AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-upIn patients with both advanced stage and HER2 under-expression (HER2 2+, 1+, triple negative) there was a significant improvement in Disease Free Survival (DFS) favoring the vaccine group (AE37 83.0% vs Control 62.5%, p = 0.039, HR 0.375)Breast Cancer Research & Treatment; article can be found online:(https://link.springer.com/article/10.1007%2Fs10549-020-05638-x)MIRAMAR, Fla., April 28, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to announce...

REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 28, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests for novel coronavirus (COVID-19 or COVID), today announced positive data for its Colloidal Gold point-of-care (POC) 2 to 10 minute fingerprick blood antibody test kits from a study of 71 patients with suspected COVID-19 infection (30 COVID PCR-Positive and 41 COVID PCR-Negative) admitted to the hospital. The data demonstrate that Colloidal Gold accurately distinguishes between COVID positive patients and COVID negative patients, as confirmed by PCR (Quest Labs), with sensitivity of 96.5% using fingerprick...

Reference is made to the stock exchange notice from Thin Film Electronics ASA (“Thinfilm”) or the “Company”) on 28 April 2020 regarding a private placement of shares in the Company raising NOK 25 million at a subscription price of NOK 0.11 per share (the “Private Placement”) and a possible subsequent offering at the same subscription price as in the private placement (the “Subsequent Offering”), subject to approval by an Extraordinary General Meeting to be held on or about 20 May 2020.Date on which the terms of the subsequent offering was announced: 28 April 2020;Last day inclusive rights to subscription rights: 28 April 2020;First day excluding rights to subscription rights: 29 April 2020;Record Date: 30 April 2020;Date of approval: Expected to be on or about 20 May 2020 by resolution of an Extraordinary General...

Los Angeles, CA, April 28, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (“UAV”), Remotely Piloted Aircraft Systems (“RPAS”), and unmanned vehicle sector (“UVS”), announced today that the CEO of the Company, Cameron Chell, will be featured on Fox Business with Liz Claman.The segment on Fox Business will focus on Draganfly’s position as a North American based drone systems developer and recent announcement it has been selected as the exclusive global systems integrator for a project with Vital Intelligence Inc., a healthcare data services and deep learning company in conjunction with the University of South Australia, using technology developed with help from the Australian Department...

– Migdal Insurance and Financial Holdings Ltd., one of Israel’s largest insurance companies, will add Blink’s EV charging stations at its owned buildings throughout Israel to accommodate its approximate 5,200 employees and its tenantsTel Aviv, April 28, 2020 (GLOBE NEWSWIRE) — Blink Charging Ltd. (Israel), a wholly-owned subsidiary of Blink Charging Co. (Nasdaq: BLNK, BLNKW) (“Blink” or the “Company”), continues its expansion through its latest agreement with Migdal Insurance and Financial Holdings Ltd. (“Migdal”), one of Israel’s largest insurance companies. This is the latest partnership that will allow Blink to expand its footprint internationally, now reaching into six countries across three continents. The company is seeing significant interest in their EV charging equipment, and network as worldwide demand for electric...

Including Partial Exercise of Over-Allotment OptionNano Dimension’s USA HQ, South Florida, April 28, 2020 (GLOBE NEWSWIRE) —  Nano Dimension Ltd. (Nasdaq, TASE: NNDM), a leading Additively Manufactured Electronics (AME)/PE (Printed Electronics) provider, today announced the closing of its underwritten public offering of 17,858,000 American Depositary Shares (the “ADSs”), or pre-funded ADS purchase warrants, each to purchase one ADS (the “Pre-Funded Warrants”) in lieu thereof. Additionally, 1,204,114 ADSs were sold pursuant to a partial exercise of the underwriter’s over-allotment option. Each ADS was sold to the public at a price per ADS of $0.70. Each Pre-Funded Warrant was sold to the public at a price per Pre-Funded Warrant of $0.6999, exercisable at any time after the date of issuance upon payment of the exercise price of $0.0001 per...

RENTON, Wash., April 28, 2020 (GLOBE NEWSWIRE) — First Financial Northwest, Inc. (the “Company”) (NASDAQ GS: FFNW), the holding company for First Financial Northwest Bank (the “Bank”), today reported net income for the quarter ended March 31, 2020, of $1.7 million, or $0.17 per diluted share, compared to net income of $2.6 million, or $0.26 per diluted share, for the quarter ended December 31, 2019, and $1.9 million, or $0.19 per diluted share, for the quarter ended March 31, 2019.“In response to the current situation surrounding the global COVID-19 pandemic, we are providing assistance to our customers in a variety of ways, including participating in the Paycheck Protection Program offered under the Coronavirus Aid, Relief, and Economic Security Act as a Small Business Administration lender, working with our customers to modify...

NESS-ZIONA, Israel, April 28, 2020 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that the Company’s annual financial statements and management discussion and analysis for the year ended December 31, 2019 are now available to download on the Company’s website at www.vaxil-bio.com/ and on Sedar at www.sedar.com. The following is a summary of the activities of the Company in 2019 and through to the date of this release:Financial HighlightsThe Company ended the year with cash on hand of $83 thousand. However, the Company now has approximately $1.3 million in cash, following the completion of a bridge financing in March 2020 and the exercise of an aggregate of 13,880,000 warrants...